Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phosphoproteomics of tau from tau knockout mice expressing tau in hippocampal neurons during spatial reference learning

ABSTRACT: This dataset describes the mass spectrometric identification of phosphorylation sites on tau protein isolated from the hippocampus of tau knockout (tau‑/‑) mice during spatial reference learning. Tau expression was selectively reintroduced into hippocampal neurons using adeno‑associated viral (AAV) vectors to enable controlled investigation of tau phosphorylation under defined behavioural conditions. Tau‑/‑ mice received bilateral injections into the dorsal and ventral hippocampus with either AAV‑syn1‑d2tTA‑tau or the control vector AAV‑syn1‑d2tTA‑eGFP. Following postoperative recovery, mice were trained in a spatial reference learning paradigm (day 2 of Morris water maze). Temporal control of tau or eGFP expression was achieved using the doxycycline-regulated d2tTA system, with induction on day 2 of training. Hippocampal tissue was collected at this time point for biochemical analysis. Tau protein was immunoprecipitated from hippocampal lysates and subjected to bottom‑up proteomic analysis. Immunoprecipitated material was reduced, alkylated, and digested with trypsin. Phosphopeptides were subsequently enriched using titanium dioxide (TiO₂) affinity chromatography. Enriched phosphopeptides underwent buffer exchange, vacuum centrifugation, and resuspension prior to liquid chromatography–tandem mass spectrometry (LC‑MS/MS) analysis.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human) Mus Musculus (mouse)

TISSUE(S): Brain

SUBMITTER: Arne Ittner

LAB HEAD: Arne Ittner

PROVIDER: PXD076789 | Pride | 2026-04-10

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	AP041124_Arne_3.raw	Raw
	AP041124_Arne_4.raw	Raw
	AP041124_Arne_5.raw	Raw
	AP041124_Arne_6.raw	Raw
	F014325.dat	Other

Items per page:

1 - 5 of 9

Similar Datasets

Phosphoproteomics of tau from tau knockout mice expressing tau or phospho-deficient tauT205A in active hippocampal cells upon fear conditioning

Project description:This dataset describes the mass spectrometric identification of tau phosphorylation sites in hippocampal neurons active during fear memory encoding. Tau knockout (tau‑/‑) mice were used as a background to selectively express human 2N4R tau variants in behaviourally activated neuronal populations. Tau‑/‑ mice received bilateral injections into the dorsal and ventral hippocampus with doxycycline‑regulated AAV vectors under control of the robust activity‑marking (RAM) promoter. Experimental groups expressed either wild‑type human 2N4R tau (tauWT; n = 4), a phosphorylation‑deficient tau mutant (tauT205A; n = 4), or eGFP as a negative control (n = 2). Following postoperative recovery, mice underwent fear conditioning. Hippocampal tissue was collected 120 minutes after conditioning, prior to induction of transgene expression. Temporal control of tau, tauT205A, or eGFP expression was achieved by doxycycline withdrawal, allowing expression during a defined 20‑hour window corresponding to neuronal activity associated with fear memory encoding. Tau protein was subsequently immunoprecipitated from hippocampal lysates and subjected to bottom‑up phosphoproteomic analysis. Immunoprecipitated tau was reduced, alkylated, and digested with trypsin, followed by enrichment of phosphopeptides using titanium dioxide (TiO₂) affinity chromatography. Enriched phosphopeptides were buffer‑exchanged, dried by vacuum centrifugation, resuspended, and analysed by liquid chromatography–tandem mass spectrometry (LC‑MS/MS). This dataset enables comparative analysis of tau phosphorylation patterns associated with neuronal activation during fear learning and provides insight into the role of the T205 phosphorylation site in activity‑dependent tau regulation.

2026-04-10 | PXD076837 | Pride

Identification of TDP-43 - TAU interactions by XL-MS

Project description:Identification of TDP-43 - TAU interactions by XL-MS (DSS). The interactions were identified in for equimolar amount of TDP-43 - TAU and, as control, TDP-43 and MBP. After 30 minutes from the induction of phase separation, samples were either analyzed (bulk condition) or subjected to centrifugation (10min at 21’000g) to pellet the formed condensates.

2025-08-25 | PXD063858 | Pride

Cancer-specific association between Tau (MAPT) and cellular pathways, clinical outcome, and drug response

Project description:Tau (MAPT) is a microtubule-associated protein causing frequent neurodegenerative diseases or inherited frontotemporal lobar degenerations. Emerging evidence for non-canonical functions of Tau in DNA protection and P53 regulation suggests its involvement in cancer. Indeed, Tau expression correlates with cancer-specific survival or response to microtubule therapeutics. These data may imply common molecular pathways involved in the pathogenesis of neurodegenerative disorders and cancer. To bring new evidence that Tau represents a key protein in cancer, we present an in silico pan-cancer analysis of MAPT transcriptomic profile in over 11000 clinical samples and over 1300 pre-clinical samples provided by the TCGA and the DEPMAP datasets respectively. We completed this analysis by exploring a possible interplay of MAPT with wild-type or mutated P53. Then, we calculated the impact of MAPT expression on clinical outcome and drug response. Overall, the results support a relevant role of the MAPT gene in several cancer types, although the contribution of Tau to cancer appears to very much depend on the cellular context.

2022-11-27 | E-MTAB-8166 | biostudies-arrayexpress

Whole genome gene expression analysis of a genomic mouse model of tauopathy

Project description:The goal of this study was to assess the number and types of differentially expressed genes in a transgenic (genomic) mouse model of tau pathology. Notably, we crossed previously described genomic mouse line called â8câ that expresses all isoforms of human tau protein (Duff et al., Neurobiology of Disease, 2000;7(2):87) with a mouse tau knockout line (Dawson et al., J Cell Sci 2001;114:1179) and generated humanized mice line called âhTau Dk/Dkâ. These mice are complete knockout of endogenous mouse tau and express all six isoforms of human tau driven by the endogenous human tau promoter. We performed microarray analysis in the hippocampal tissue from six-month old hTau Dk/Dk mice (n=3) and compared it with age-matched non-transgenic control group. Both the lines are in C57BL/6J genetic background.

2017-03-15 | E-MTAB-5078 | biostudies-arrayexpress

Properties of Alzheimer’s disease brain-derived tau aggregates define tau processing by human astrocytes

Project description:The templated misfolding of tau proteins accounts for tau pathology spread in Alzheimer’s disease (AD). Post-translational modifications, including phosphorylation at specific residues, are closely linked with tau seeding ability and clinical disease progression. This study investigates the role of astrocytes in tau spread, demonstrating that tau aggregates from post-mortem AD brain are internalized and processed by human astrocytes. Differences in tau internalization, clearance, and seeding were observed, potentially reflecting the molecular properties of tau. A direct relationship between tau handling by astrocytes and astrocyte responses was noted in transcriptomic data, highlighting dysregulated genes linked to pathological tau clearance pathways. To explore these differences, mass spectrometry was performed on both control and AD brain extracts, providing insights into the complex interplay between tau diversity and astrocyte responses in AD.

2025-05-07 | PXD056614 | Pride

Study of the conformational dynamics of Helicobacter pylori CtpA

Project description:Bacterial carboxyl-terminal processing proteases (CTPs) are critical for maintaining protein quality control, mediating signal transduction, and enabling cellular adaptation. Their activation typically involves substrate binding to the PDZ domain or interaction with an adaptor protein. In this study, we employed hydrogen–deuterium exchange mass spectrometry (HDX-MS) to investigate the conformational dynamics of the CTP from Helicobacter pylori, CtpA, in both the presence and absence of its substrate HP1076. To eliminate the confounding effects of proteolysis, a triple mutant (CtpATM) with an inactivated catalytic triad was used. Additionally, a hinge-region mutant (CtpAF105R) was employed to validate the dynamic behavior of the linker connecting the PDZ domain. This study reveals CtpA transitions between resting and active states independently of substrate binding.

2025-10-04 | PXD068881 | Pride

Identification of proteins that interact with extracellularly applied fibrillar Tau assemblies

Project description:The microtubule associated protein Tau (MAPT) expressed in neurons is involved in microtubules stabilization, cell morphogenesis and axonal transport. In pathological conditions, Tau assembles into high molecular weight assemblies leading to neuropathological Tau deposits, the hallmark of several neurodegenerative diseases collectively named “tauopathies”, including Alzheimer’s disease. These pathologic Tau assemblies are released by affected neuronal cells and taken up by naïve neighbor cells, propagate from one cell to another and amplify by seeding the aggregation of endogenous Tau. In order to identify plasma membrane proteins exposed extracellularly that interact with extracellularly applied fibrillar Tau assemblies, we exposed pure-neuronal cultures to fibrillar Tau for 10 min, pulled down the associated proteins, and identified them using a proteomic-based approach. Of the six Tau isoforms produced by alternative splicing of the MAPT gene and differing from each other by the presence or absence of one or two inserts in the N-terminal part (0N, 1N or 2N) of the protein and by the presence of either three or four repeated microtubule binding motifs in the protein C-terminal part (3R or 4R), we have expressed and purified 1N3R and 1N4R Tau isoforms and further assembled them into 1N3R and 1N4R Tau fibrils. Using pull-down of whole cell lysates and mass spectrometry, we have identified proteins interacting with extracellularly applied Tau fibrils. We have performed two different experiments with either 1N3R Tau fibrils or 1N4R Tau fibrils (condition 1 and condition 2 respectively). Each condition consists in six experimental replicates of cells exposed 10 min to Tau fibrils and of the non-treated cells used as controls.

2019-01-09 | PXD009294 | Pride

The Proteoform Landscape of Tau from the Human Brain

Project description:Tau is a microtubule-associated protein (MAP) and critical for maintaining the cytoskeleton of neurons. Tau and its post-translational modifications (PTMs) have been studied for decades, yet the exact composition of intact tau and its truncation products present in the human brain have evaded study at the proteoform level. Here, our project shows tau proteoform profiling and exact characterization is possible using immunoprecipitation (IP) and the new approach of individual ion mass spectrometry (I2MS). We provide a first glimpse of the tau proteoform landscape present in the CHAPS-soluble extracts from the temporal cortex of a control subject and a donor with Alzheimer’s Disease (AD). Profiling and identification of four isoforms (0N3R, 1N3R, 0N4R, and 1N4R), truncated products (e.g., 72-172 derived from the 0N3R/0N4R isoforms), and intact tau proteoforms harboring PTMs including phosphorylation, methylation, and acetylation. The specific tau proteoform identification typically employs proton transfer charge reduction (PTCR) and electron transfer dissociation (ETD) with spectral readout by individual ion tandem mass spectrometry (I2MS2). A precise understanding of the tau proteoform landscape over the course of neurodegeneration is critical to understand AD pathology vs. related dementias. The assay approach reported here, termed ‘TauFormA’, will advance AD research, and gives a sense of what is technologically possible for new biomarker discovery and to assist the development of therapeutics using the most exact kind of compositional information on tau.

2025-10-15 | PXD061278 | Pride

Combinatorial native MS and LC-MS/MS approach reveals high intrinsic phosphorylation of human Tau

Project description:Abnormal changes in the neuronal microtubule-associated protein Tau, such as high phosphorylation and aggregation, are considered hallmarks of cognitive deficits in Alzheimer disease. Abnormal phosphorylation is thought to take place before aggregation, and therefore it is often assumed that phosphorylation predisposes Tau towards aggregation. However, the nature and extent of phosphorylation has remained ill-defined. Tau protein contains up to 85 potential phosphorylation sites (80 Ser/Thr, and 5 Tyr P-sites), many of which can be phosphorylated by various kinases because the unfolded structure of Tau makes them accessible. However, limitations in methods (e.g. in mass spectrometry of phosphorylated peptides, or antibodies against phospho-epitopes) have led to conflicting results regarding the overall degree of phosphorylation of Tau in cells. Here we present results from a new approach, that is based on native mass spectrometry analysis of intact Tau expressed in a eukaryotic cell system (Sf9) which reveals Tau in different phosphorylation states. The extent of phosphorylation is remarkably heterogeneous with up to ~20 phosphates (Pi) per molecule and distributed over 51 sites (including all P-sites published so far and additional 18 P-sites). The medium phosphorylated fraction Pm showed overall occupancies centered at 8 Pi (± 5 Pi) with a bell-shaped distribution, the highly phosphorylated fraction Ph had 14 Pi (± 6 Pi). The distribution of sites was remarkably asymmetric (with 71% of all P-sites located in the C-terminal half of Tau). All phosphorylation sites were on Ser or Thr residues, but none on Tyr. Other known posttranslational modifications of Tau were near or below our detection limit (e.g. acetylation, ubiquitination).

2020-11-20 | PXD020985 | Pride

Bassoon contributes to tau-seed neurotoxicity and propagation.

Project description:Tau aggregates are critical pathological features of Alzheimer’s disease (AD) and other tauopathies. Growing evidence suggests that soluble tau aggregates trigger neurodegenerative phenotypes. However, the nature of the tau species and interactors involved in its aggregation and spreading remains unclear. By using size exclusion chromatography, mass spectrometry, and bioinformatic analysis, we identified Bassoon protein (BSN) as a significant tau interactor in PS19 mice, as well as in human AD and PSP cases. We also found that overexpression of BSN triggers the aggregation of tau and increase the tau seeding activity in vitro, and also exacerbates the degenerative phenotype in a Fly model for tauopathy. Knockdown of BSN significantly reduced tau spreading in PS19 mouse brains and destabilized the tau aggregates, leading to a reduction in the tau pathology in this model. Furthermore, BSN downregulation was able to restore the neurodegenerative phenotype in PS19 mice, observed in electrophysiology and behavioral tests. Our results identify BSN as a key interactor of tau spread and aggregation in the brain, and therefore a potential target for the treatment of diseases that involve tau spread and aggregation.

2023-03-11 | PXD027451 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data